 |
|
|
| |
Triple Combination Drug Interaction Studies of the Nucleotide Analog, AL-335, in Combination with Simeprevir and Odalasvir Demonstrate Significant Synergy in the Hepatitis C Virus (HCV) Subgenomic Replicon System
|
| |
| |
Reported by Jules Levin
AASD 2016 Nov 11-15 Boston, MA
Hua Tan, Kenneth Shaw, Andreas Jekle, Soon Kang, Guangyi Wang, David B. Smith, Leonid Beigelman Lawrence M. Blatt and Julian A. Symons*
Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies, 260 E. Grand Avenue, South San Francisco, CA, USA.
EASL/Paris-2016: Short duration treatment with AL-335 and odalasvir (ODV), with or without simeprevir (SMV), in treatment naïve patients with hepatitis C virus (HCV) genotype (GT) 1 infection - (09/26/16)
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen's Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV - (09/26/16)
|
| |
|
|
|
|
|
